middle.news
Radiopharm Theranostics Launches First Human Trial of Novel Prostate Cancer Therapy
8:40am on Tuesday 18th of November, 2025 AEDT
•
Healthcare
Read Story
Radiopharm Theranostics Launches First Human Trial of Novel Prostate Cancer Therapy
8:40am on Tuesday 18th of November, 2025 AEDT
Key Points
HREC approval granted for Phase 1 trial of RAD 402 in advanced prostate cancer
RAD 402 combines a KLK3-targeting monoclonal antibody with terbium-161 radionuclide
Preclinical studies show strong tumour targeting and favourable biodistribution
First company-sponsored therapeutic trial employing terbium-161
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE